\-\ Texto\\:\\ \ \(0\)\
\-\ general\\:\\ \\ alert\\,\\ active\\,\\ in\\ nad\ \(0\)\
\-\ vitals\\:\\ \\ pulse\\ 117\\,\\ respirations\\ 24\\,\\ bp\\ 111\\/69\\,\\ temp\\.\\ 37\\.3\ \(0\)\
\-\ heent\\:\\ \\ eyes\\ are\\ normal\\ without\\ lisch\\ nodules\ \(0\)\
\-\ skin\\:\\ \\ multiple\\ cafe\\-au\\-lait\\ spots\\,\\ one\\ large\\ spot\\ over\\ back\\ and\\ thigh\\,\\ a\\ total\\ of\\ 10\\-15\\ spots\\ \\>1cm\ \(0\)\
\-\ ms\\:\\ \\ back\\ is\\ straight\\ without\\ evidence\\ of\\ scoliosis\ \(0\)\
\-\ no\\ treatment\\,\\ a\\ follow\\-up\\ mri\\ will\\ be\\ obtained\\ to\\ ensure\\ no\\ growth\\.\\ \\ however\\,\\ the\\ national\\ neurofibromatosis\\ foundation\\ does\\ not\\ recommend\\ neuroimaging\\ for\\ screening\\ in\\ asymptomatic\\ children\\ with\\ nf1\\.\ \(0\)\
\-\ yearly\\ ophthamologic\\ exam\\ to\\ evaluate\\ for\\ lisch\\ nodules\\ and\\ optic\\ gliomas\\.\ \(0\)\
\-\ yearly\\ bp\\ check\\ since\\ hypertension\\ is\\ frequent\\ in\\ patients\\ with\\ nf1\\ and\\ can\\ occur\\ at\\ any\\ age\\.\ \(0\)\
\-\ regular\\ growth\\ assessments\\ since\\ most\\ nf1\\ patients\\ have\\ short\\ stature\\ and\\ check\\ for\\ scoliosis\\ which\\ occurs\\ in\\ 10\\-25\\%\\ of\\ affected\\ individuals\\.\ \(0\)\
\-\ developmental\\ evaluations\\.\ \(0\)\
\-\ increase\\ signal\\ in\\ globus\\ pallidus\\ bilaterally\\ which\\ does\\ not\\ enhance\\.\\ \\ there\\ are\\ also\\ area\\ of\\ abnormal\\ signal\\ in\\ the\\ cerebellum\\.\ \(0\)\
\-\ hamartoma\\ 2nd\\ to\\ nf\\-1\ \(0\)\
\-\ hamartoma\ \(55\)\
\-\ low\\ grade\\ tumor\ \(0\)\
\-\ heterotopias\ \(3\)\
\-\ myelination\\ disorder\ \(0\)\
\-\ gliosis\ \(20\)\
\-\ the\\ patient\\ is\\ a\\ 7\\ y\\/o\\ caucasian\\ male\\ who\\ presented\\ for\\ evaluation\\ after\\ confirmation\\ of\\ a\\ positive\\ family\\ history\\ of\\ neurofibromatosis\\ type\\ 1\\ \\(mother\\,\\ older\\ brother\\,\\ and\\ maternal\\ grandmother\\)\\.\\ \\ he\\ also\\ presented\\ with\\ cafe\\-au\\-lait\\ spots\\ shortly\\ after\\ birth\\.\\ \\ developmentally\\,\\ the\\ patient\\ was\\ in\\ the\\ 25\\%\\ for\\ height\\ and\\ weight\\ and\\ 70\\%\\ for\\ head\\ circumference\\ and\\ had\\ some\\ speech\\ problems\\.\\ \\ the\\ patient\\ was\\ otherwise\\ healthy\\.\\ \\ last\\ year\\ his\\ mother\\ was\\ diagnosed\\ with\\ glioblastoma\\ multiforme\\.\ \(0\)\
\-\ a\\ hamartoma\\ is\\ a\\ lesion\\ made\\ of\\ normal\\ cells\\ in\\ an\\ abnormal\\ location\\.\\ \\ they\\ are\\ one\\ of\\ many\\ brain\\ lesions\\ seen\\ in\\ patients\\ with\\ neurofibromatosis\\ type\\ 1\\.\\ \\ the\\ important\\ aspect\\ is\\ to\\ differentiate\\ a\\ hamartoma\\ from\\ an\\ astrocytoma\\,\\ glioma\\,\\ or\\ other\\ cns\\ tumor\\.\\ \\ a\\ hamartoma\\ should\\ not\\ enhance\\ since\\ enhancement\\ usually\\ indicates\\ an\\ actively\\ growing\\ tumor\\.\\ \\ also\\,\\ there\\ should\\ be\\ very\\ little\\ or\\ no\\ growth\\.\\ \\ clinically\\,\\ the\\ patient\\ should\\ be\\ asymptomatic\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hamartoma\\:\\ 0\\.06732541350972573\ \(0\)\
\-\ spots\\:\\ 0\\.051720216829195524\ \(0\)\
\-\ nf1\\:\\ 0\\.051720216829195524\ \(0\)\
\-\ cafe\\-au\\-lait\\:\\ 0\\.044477845160221255\ \(0\)\
\-\ lisch\\:\\ 0\\.042819735232545286\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.04081706508712736\ \(0\)\
\-\ yearly\\:\\ 0\\.03326222470457103\ \(0\)\
\-\ check\\:\\ 0\\.03299409781330364\ \(0\)\
\-\ growth\\:\\ 0\\.03212379247385274\ \(0\)\
\-\ scoliosis\\:\\ 0\\.03083448139001021\ \(0\)\
\-\ since\\:\\ 0\\.02713629355935058\ \(0\)\
\-\ 111\\/69\\:\\ 0\\.025404952230451004\ \(0\)\
\-\ ophthamologic\\:\\ 0\\.025404952230451004\ \(0\)\
\-\ enhance\\:\\ 0\\.023823557330503044\ \(0\)\
\-\ should\\:\\ 0\\.023552235232468015\ \(0\)\
\-\ 37\\.3\\:\\ 0\\.02340740992336182\ \(0\)\
\-\ mother\\:\\ 0\\.022494890710261936\ \(0\)\
\-\ 117\\:\\ 0\\.021409867616272643\ \(0\)\
\-\ bp\\:\\ 0\\.021380823919688284\ \(0\)\
\-\ foundation\\:\\ 0\\.020766802626894516\ \(0\)\
\-\ 10\\-25\\:\\ 0\\.020766802626894516\ \(0\)\
\-\ myelination\\:\\ 0\\.020766802626894516\ \(0\)\
\-\ nodules\\:\\ 0\\.02041797616946831\ \(0\)\
\-\ assessments\\:\\ 0\\.02024138027302145\ \(0\)\
\-\ nf\\-1\\:\\ 0\\.019797142002625893\ \(0\)\
\-\ heterotopias\\:\\ 0\\.019797142002625893\ \(0\)\
\-\ grandmother\\:\\ 0\\.019797142002625893\ \(0\)\
\-\ developmentally\\:\\ 0\\.019797142002625893\ \(0\)\
\-\ patients\\:\\ 0\\.019120241493078036\ \(0\)\
\-\ actively\\:\\ 0\\.019072892929770255\ \(0\)\
\-\ pallidus\\:\\ 0\\.018769260319805338\ \(0\)\
\-\ evaluations\\:\\ 0\\.018494591213741002\ \(0\)\
\-\ brother\\:\\ 0\\.01779959969553671\ \(0\)\
\-\ national\\:\\ 0\\.017414783002094283\ \(0\)\
\-\ stature\\:\\ 0\\.017414783002094283\ \(0\)\
\-\ globus\\:\\ 0\\.017414783002094283\ \(0\)\
\-\ neuroimaging\\:\\ 0\\.017240072276398507\ \(0\)\
\-\ gliosis\\:\\ 0\\.017240072276398507\ \(0\)\
\-\ \\%\\:\\ 0\\.01723332305486462\ \(0\)\
\-\ tumor\\:\\ 0\\.01722391038856609\ \(0\)\
\-\ does\\:\\ 0\\.01680473239414413\ \(0\)\
\-\ 10\\-15\\:\\ 0\\.016771718012716156\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.016648947538882346\ \(0\)\
\-\ type\\:\\ 0\\.016603021489031183\ \(0\)\
\-\ recommend\\:\\ 0\\.016368945844488034\ \(0\)\
\-\ \\:\\:\\ 0\\.016286380633871254\ \(0\)\
\-\ back\\:\\ 0\\.016248220953011396\ \(0\)\
\-\ gliomas\\:\\ 0\\.01624629565884309\ \(0\)\
\-\ respirations\\:\\ 0\\.015906863279429882\ \(0\)\
\-\ circumference\\:\\ 0\\.015906863279429882\ \(0\)\
\-\ maternal\\:\\ 0\\.015508735502828103\ \(0\)\
\-\ 1cm\\:\\ 0\\.015328561563400626\ \(0\)\
\-\ confirmation\\:\\ 0\\.014774175705626977\ \(0\)\
\-\ also\\:\\ 0\\.01456443452740765\ \(0\)\
\-\ differentiate\\:\\ 0\\.014499506599562641\ \(0\)\
\-\ indicates\\:\\ 0\\.014499506599562641\ \(0\)\
\-\ individuals\\:\\ 0\\.014371403537398856\ \(0\)\
\-\ ensure\\:\\ 0\\.014309426000739018\ \(0\)\
\-\ multiforme\\:\\ 0\\.014309426000739018\ \(0\)\
\-\ speech\\:\\ 0\\.014189331774800782\ \(0\)\
\-\ abnormal\\:\\ 0\\.014046641154552801\ \(0\)\
\-\ shortly\\:\\ 0\\.014018082724452652\ \(0\)\
\-\ nad\\:\\ 0\\.013654123861846622\ \(0\)\
\-\ temp\\:\\ 0\\.013654123861846622\ \(0\)\
\-\ growing\\:\\ 0\\.013605688362375785\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.013558053486435696\ \(0\)\
\-\ thigh\\:\\ 0\\.013465082701945146\ \(0\)\
\-\ presented\\:\\ 0\\.01342569242087844\ \(0\)\
\-\ little\\:\\ 0\\.013375017735074525\ \(0\)\
\-\ one\\:\\ 0\\.013347154947035412\ \(0\)\
\-\ eyes\\:\\ 0\\.013244987662220147\ \(0\)\
\-\ spot\\:\\ 0\\.013244987662220147\ \(0\)\
\-\ ms\\:\\ 0\\.013161450091980227\ \(0\)\
\-\ straight\\:\\ 0\\.013161450091980227\ \(0\)\
\-\ signal\\:\\ 0\\.012986019194655784\ \(0\)\
\-\ height\\:\\ 0\\.01296262337299766\ \(0\)\
\-\ pulse\\:\\ 0\\.012705473131706757\ \(0\)\
\-\ for\\:\\ 0\\.012607057325234268\ \(0\)\
\-\ cns\\:\\ 0\\.012601922672842021\ \(0\)\
\-\ \\,\\:\\ 0\\.012482308496474345\ \(0\)\
\-\ older\\:\\ 0\\.012405357110805903\ \(0\)\
\-\ frequent\\:\\ 0\\.01231188369364984\ \(0\)\
\-\ alert\\:\\ 0\\.012281387701342817\ \(0\)\
\-\ 2nd\\:\\ 0\\.012281387701342817\ \(0\)\
\-\ cerebellum\\:\\ 0\\.012251211044664732\ \(0\)\
\-\ heent\\:\\ 0\\.011911778665251522\ \(0\)\
\-\ birth\\:\\ 0\\.011832819085458687\ \(0\)\
\-\ 70\\:\\ 0\\.011832819085458687\ \(0\)\
\-\ vitals\\:\\ 0\\.011781356211107081\ \(0\)\
\-\ caucasian\\:\\ 0\\.011755965347469748\ \(0\)\
\-\ short\\:\\ 0\\.011608146055286607\ \(0\)\
\-\ without\\:\\ 0\\.011596617673534064\ \(0\)\
\-\ developmental\\:\\ 0\\.011444758897717311\ \(0\)\
\-\ optic\\:\\ 0\\.011399729163126298\ \(0\)\
\-\ problems\\:\\ 0\\.011399729163126298\ \(0\)\
\-\ be\\:\\ 0\\.011392709423722731\ \(0\)\
\-\ regular\\:\\ 0\\.011355392221225783\ \(0\)\
\-\ healthy\\:\\ 0\\.01110280632192101\ \(0\)\
\-\ glioma\\:\\ 0\\.01110280632192101\ \(0\)\
\-\ disorder\\:\\ 0\\.011062780062091998\ \(0\)\
\-\ important\\:\\ 0\\.011062780062091998\ \(0\)\
\-\ in\\:\\ 0\\.010929611156375488\ \(0\)\
\-\ clinically\\:\\ 0\\.010797159140479155\ \(0\)\
\-\ not\\:\\ 0\\.010675665749930278\ \(0\)\
\-\ affected\\:\\ 0\\.010655690523198107\ \(0\)\
\-\ children\\:\\ 0\\.01063848543101798\ \(0\)\
\-\ total\\:\\ 0\\.010604380365752841\ \(0\)\
\-\ last\\:\\ 0\\.010520842795512922\ \(0\)\
\-\ screening\\:\\ 0\\.010504421985384283\ \(0\)\
\-\ general\\:\\ 0\\.010376318923220496\ \(0\)\
\-\ increase\\:\\ 0\\.010329711259688505\ \(0\)\
\-\ an\\:\\ 0\\.010216122745977493\ \(0\)\
\-\ after\\:\\ 0\\.010190208660571772\ \(0\)\
\-\ many\\:\\ 0\\.010121652783594877\ \(0\)\
\-\ occurs\\:\\ 0\\.010107350797018135\ \(0\)\
\-\ family\\:\\ 0\\.010093119437823372\ \(0\)\
\-\ are\\:\\ 0\\.010070955670284742\ \(0\)\
\-\ evaluate\\:\\ 0\\.00995454253100021\ \(0\)\
\-\ 25\\:\\ 0\\.00995454253100021\ \(0\)\
\-\ cells\\:\\ 0\\.009874486150288176\ \(0\)\
\-\ patient\\:\\ 0\\.009874258569641359\ \(0\)\
\-\ made\\:\\ 0\\.009809430467179995\ \(0\)\
\-\ hypertension\\:\\ 0\\.009708302744380944\ \(0\)\
\-\ 24\\:\\ 0\\.009574803978749134\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.009562968872257337\ \(0\)\
\-\ skin\\:\\ 0\\.009458584827778034\ \(0\)\
\-\ 7\\:\\ 0\\.009435893022501649\ \(0\)\
\-\ active\\:\\ 0\\.00940218685603712\ \(0\)\
\-\ grade\\:\\ 0\\.009379933120896168\ \(0\)\
\-\ occur\\:\\ 0\\.009239327460465529\ \(0\)\
\-\ which\\:\\ 0\\.009193916929351864\ \(0\)\
\-\ a\\:\\ 0\\.00914351128112049\ \(0\)\
\-\ diagnosed\\:\\ 0\\.00905531745474065\ \(0\)\
\-\ very\\:\\ 0\\.008938863453766942\ \(0\)\
\-\ they\\:\\ 0\\.008873043592182437\ \(0\)\
\-\ otherwise\\:\\ 0\\.00884528885713644\ \(0\)\
\-\ weight\\:\\ 0\\.00882693309838866\ \(0\)\
\-\ obtained\\:\\ 0\\.008754657350846805\ \(0\)\
\-\ location\\:\\ 0\\.008589935697129375\ \(0\)\
\-\ was\\:\\ 0\\.008544186071011702\ \(0\)\
\-\ \\>\\:\\ 0\\.008182038947171654\ \(0\)\
\-\ is\\:\\ 0\\.008102172599203539\ \(0\)\
\-\ bilaterally\\:\\ 0\\.008088487719089058\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.00801163398110012\ \(0\)\
\-\ positive\\:\\ 0\\.007991024755862008\ \(0\)\
\-\ area\\:\\ 0\\.0077862715969287235\ \(0\)\
\-\ any\\:\\ 0\\.007754567818652143\ \(0\)\
\-\ aspect\\:\\ 0\\.00773571162675319\ \(0\)\
\-\ normal\\:\\ 0\\.0077211092484098034\ \(0\)\
\-\ will\\:\\ 0\\.007704556248931244\ \(0\)\
\-\ 1\\.\\:\\ 0\\.007692187799128532\ \(0\)\
\-\ age\\:\\ 0\\.0074954188056031885\ \(0\)\
\-\ some\\:\\ 0\\.0074781794059560775\ \(0\)\
\-\ usually\\:\\ 0\\.0074781794059560775\ \(0\)\
\-\ no\\:\\ 0\\.0074389984210703345\ \(0\)\
\-\ brain\\:\\ 0\\.007410234937471936\ \(0\)\
\-\ there\\:\\ 0\\.007329772659740569\ \(0\)\
\-\ evaluation\\:\\ 0\\.007153425924572933\ \(0\)\
\-\ his\\:\\ 0\\.007097662903881648\ \(0\)\
\-\ head\\:\\ 0\\.0069844418172158385\ \(0\)\
\-\ he\\:\\ 0\\.006870856893466915\ \(0\)\
\-\ however\\:\\ 0\\.00685696845993392\ \(0\)\
\-\ low\\:\\ 0\\.00684774655004726\ \(0\)\
\-\ y\\/o\\:\\ 0\\.006820256570085419\ \(0\)\
\-\ enhancement\\:\\ 0\\.006600832179028922\ \(0\)\
\-\ lesions\\:\\ 0\\.006592393390040195\ \(0\)\
\-\ evidence\\:\\ 0\\.006456606868492443\ \(0\)\
\-\ who\\:\\ 0\\.006420658239601446\ \(0\)\
\-\ over\\:\\ 0\\.0062698633721612745\ \(0\)\
\-\ 1\\:\\ 0\\.005859730167030855\ \(0\)\
\-\ or\\:\\ 0\\.005772465411894567\ \(0\)\
\-\ most\\:\\ 0\\.005685403866651516\ \(0\)\
\-\ other\\:\\ 0\\.005676191783004174\ \(0\)\
\-\ mri\\:\\ 0\\.005657855489667492\ \(0\)\
\-\ can\\:\\ 0\\.005585655194435359\ \(0\)\
\-\ exam\\:\\ 0\\.005409896080546219\ \(0\)\
\-\ large\\:\\ 0\\.005384848506717809\ \(0\)\
\-\ have\\:\\ 0\\.005332674577421014\ \(0\)\
\-\ had\\:\\ 0\\.005313688239886767\ \(0\)\
\-\ multiple\\:\\ 0\\.005186760816943138\ \(0\)\
\-\ lesion\\:\\ 0\\.005016009296831281\ \(0\)\
\-\ treatment\\:\\ 0\\.004984486915276331\ \(0\)\
\-\ to\\:\\ 0\\.004922975313463818\ \(0\)\
\-\ seen\\:\\ 0\\.004866362003076917\ \(0\)\
\-\ male\\:\\ 0\\.004453041895929317\ \(0\)\
\-\ and\\:\\ 0\\.004150063532731261\ \(0\)\
\-\ from\\:\\ 0\\.0036496706430957124\ \(0\)\
\-\ history\\:\\ 0\\.0034011946331616236\ \(0\)\
\-\ at\\:\\ 0\\.0033364932358260313\ \(0\)\
\-\ the\\:\\ 0\\.003187303393743534\ \(0\)\
\-\ year\\:\\ 0\\.002755346597328284\ \(0\)\
\-\ of\\:\\ 0\\.002685966589002615\ \(0\)\
\-\ \\(\\:\\ 0\\.0020817340813944108\ \(0\)\
\-\ \\)\\:\\ 0\\.002056304588222781\ \(0\)\
\-\ \\.\\:\\ 0\\.0019437786335722745\ \(0\)\
\-\ with\\:\\ 0\\.001685939136741927\ \(0\)\
